Sanofi-Aventis

SNY-N

NYSE:SNY

45.51
0.63 (1.37%)
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales.
More at Wikipedia

Analysis and Opinions about SNY-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
May 1, 2017

The ADR trades in New York. He does well buying drug companies when out of favour. They all face patent cliffs from time to time. The made acquisitions of some promising new drugs. They have an exemplary balance sheet. People hated it because they were in France with an election pending. (Analysts’ target: $47.00).

Show full opinionHide full opinion

The ADR trades in New York. He does well buying drug companies when out of favour. They all face patent cliffs from time to time. The made acquisitions of some promising new drugs. They have an exemplary balance sheet. People hated it because they were in France with an election pending. (Analysts’ target: $47.00).

COMMENT
COMMENT
December 28, 2016

Healthcare stocks are totally out of favour and look interesting. As this is in Europe, it is somewhat out of the grasp of what might happen in the US regulatory market.

Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
December 28, 2016

Healthcare stocks are totally out of favour and look interesting. As this is in Europe, it is somewhat out of the grasp of what might happen in the US regulatory market.

TOP PICK
TOP PICK
July 25, 2016

French drug stock. People hate French investments and people don’t like drug stocks. They are facing a patent cliff. The stock is down and this is historically the best place to buy drug stocks. They will likely make acquisitions with their hoard of cash.

Show full opinionHide full opinion

French drug stock. People hate French investments and people don’t like drug stocks. They are facing a patent cliff. The stock is down and this is historically the best place to buy drug stocks. They will likely make acquisitions with their hoard of cash.

DON'T BUY
DON'T BUY
November 20, 2014

The big drop was related to the poor performance of the diabetes drug. When the CEO gets let go after announcing poor earnings it is not a catalyst. He wonders if they have a proper pipeline. He suggests staying away from it although there is some definite value here.

Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
November 20, 2014

The big drop was related to the poor performance of the diabetes drug. When the CEO gets let go after announcing poor earnings it is not a catalyst. He wonders if they have a proper pipeline. He suggests staying away from it although there is some definite value here.

WEAK BUY
WEAK BUY
April 29, 2014

They missed their numbers by a little bit. They had a nice run, 3.7% yield, 14 times earnings. This would be a great company to buy and sell off its parts. It is not huge in any particular area. It will benefit from the possibility of takeovers in the industry. You get a good rate of return but you won’t get a huge upside.

Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
April 29, 2014

They missed their numbers by a little bit. They had a nice run, 3.7% yield, 14 times earnings. This would be a great company to buy and sell off its parts. It is not huge in any particular area. It will benefit from the possibility of takeovers in the industry. You get a good rate of return but you won’t get a huge upside.

COMMENT
COMMENT
April 9, 2014

Has looked at this recently because they have some good drugs in their pipeline, but his preference right now in Europe is Shier (?) which he thinks is well-positioned.

Show full opinionHide full opinion

Has looked at this recently because they have some good drugs in their pipeline, but his preference right now in Europe is Shier (?) which he thinks is well-positioned.

BUY
BUY
August 11, 2011
One of the largest and most popular drug companies in Europe. Has a strong product profile. French stocks, merely by their association, have been really hammered. Good stable business that will do well, irrespective of economic conditions. Good entry point.
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
August 11, 2011
One of the largest and most popular drug companies in Europe. Has a strong product profile. French stocks, merely by their association, have been really hammered. Good stable business that will do well, irrespective of economic conditions. Good entry point.
DON'T BUY
DON'T BUY
May 6, 2010
PE of 8%. Might be a value trap. Not a lot of growth prospects. Vaccine business does fairly well. Pharma business is struggling a little and not much in the pipe at this point. (See Top Picks.)
Show full opinionHide full opinion
PE of 8%. Might be a value trap. Not a lot of growth prospects. Vaccine business does fairly well. Pharma business is struggling a little and not much in the pipe at this point. (See Top Picks.)
BUY
BUY
July 4, 2008
Many of the health care stocks have started to recover or they are not down as much as the market this year. 4% yield and decent growth over time.
Show full opinionHide full opinion
Many of the health care stocks have started to recover or they are not down as much as the market this year. 4% yield and decent growth over time.
BUY
BUY
July 13, 2005
Had as a toe-hold in the pharmaceutical group that has been out of favour for 3 years, but with only medium success. Facing competition from the generics. Has a great portfolio of drugs and has pretty steady growth.
Show full opinionHide full opinion
Had as a toe-hold in the pharmaceutical group that has been out of favour for 3 years, but with only medium success. Facing competition from the generics. Has a great portfolio of drugs and has pretty steady growth.
BUY
BUY
May 3, 2005
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
Show full opinionHide full opinion
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
Showing 16 to 26 of 26 entries